scholarly journals Antimicrobial Activity and Spectrum of Cefovecin, a New Extended- Spectrum Cephalosporin, against Pathogens Collected from Dogs and Cats in Europe and North America

2006 ◽  
Vol 50 (7) ◽  
pp. 2286-2292 ◽  
Author(s):  
M. R. Stegemann ◽  
C. A. Passmore ◽  
J. Sherington ◽  
C. J. Lindeman ◽  
G. Papp ◽  
...  
Keyword(s):  
Bacterial Infections ◽  
Pasteurella Multocida ◽  
The United States ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Extended Spectrum ◽  
Staphylococcus Intermedius ◽  
Aerobic And Anaerobic

ABSTRACT Cefovecin is a new extended-spectrum semisynthetic cephalosporin indicated for the treatment of bacterial infections in dogs and cats. This study evaluated the in vitro activity and spectrum of cefovecin against 2,641 recent clinical isolates (1,660 canine and 981 feline isolates) from Europe and the United States. MIC determinations against cefovecin and other reference antimicrobials were performed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS). Cefovecin demonstrated bactericidal activity against both gram-positive and gram-negative pathogens. Cefovecin exhibited in vitro activity against all major aerobic and anaerobic bacterial pathogens associated with skin, urinary tract, and periodontal infections in dogs and cats. The MIC90 values of cefovecin against Staphylococcus intermedius, Escherichia coli, and Pasteurella multocida were 0.25 μg/ml, 1.0 μg/ml, and 0.06 μg/ml, respectively. No significant differences were observed in terms of the activities of cefovecin against pathogens from different European countries and against pathogens of European and U.S. origin.

scholarly journals In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance.

1997 ◽  
Vol 41 (5) ◽  
pp. 1190-1192 ◽  
Author(s):  
J L Watts ◽  
S A Salmon ◽  
M S Sanchez ◽  
R J Yancey
Keyword(s):  
Antimicrobial Agents ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Extended Spectrum ◽  
Veterinary Importance

The in vitro activity of premafloxacin against 673 veterinary pathogens was evaluated. Premafloxacin was equivalent to ciprofloxacin, enrofloxacin, and danofloxacin in activity against the gram-negative bacilli but was much more active (MIC for 90% of the strains tested [MIC90], 0.015 to 0.25 microg/ml) than the comparison antimicrobial agents (MIC90, 0.13 to 16.0 microg/ml) against the staphylococci, streptococci, and anaerobes tested.

scholarly journals 1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S413-S413 ◽  
Author(s):  
Masakatsu Tsuji ◽  
Meredith Hackel ◽  
Roger Echols ◽  
Yoshinori Yamano ◽  
Dan Sahm
Keyword(s):  
North America ◽  
Burkholderia Cepacia ◽  
Dose Range ◽  
The United States ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Wide Range

Abstract Background Cefiderocol (CFDC) is a novel parenteral siderophore cephalosporin with potent activity against a wide range of Gram-negative pathogens, including carbapenem-resistant strains. Additionally, a recently conducted in vivo murine-based study has demonstrated an incremental exposure-response profile over a dose range without the appearance of adaptive resistance. In this study, we evaluated the in vitro activity of CFDC and comparator agents against clinical isolates collected in 2015–2016 from North America from SIDERO-WT-2015 surveillance study. Methods A total of 3,602 isolates (2,470 Enterobacteriaceae, 223 A. baumannii, 85 Acinetobacter spp., 619 P. aeruginosa, 165 S. maltophilia and 17 Burkholderia cepacia, and 23 Burkholderia spp.) collected from the United States and Canada in 2015–2016 were tested. MICs were determined for CFDC, cefepime (FEP), ceftazidime–avibactam (CZA), ceftolozane–tazobactam (C/T), ciprofloxacin (CIP), colistin (CST), and meropenem (MEM) by broth microdilution and interpreted according to CLSI guidelines. As recommended by CLSI, cefiderocol was tested in iron-depleted cation-adjusted Mueller–Hinton broth (ID-CAMHB). Carbapenem nonsusceptible (Carb-NS) strains were defined as MEM MIC ≥2 µg/mL for Enterobacteriaceae, and ≥4 µg/mL for nonfermenters. Results CFDC exhibited potent in vitro activity against 3,602 strains of Gram-negative bacteria with an overall MIC90 of 0.5 mg/mL. As shown in the following table, MIC90 of CFDC against P. aeruginosa, A. baumannii, S. maltophilia, and Enterobacteriaceae including the subset of Carb-NS isolates were 0.5, 2, 0.5 and 0.5 mg/mL, respectively. At 4 mg/mL, CFDC inhibited the growth of 99.6% of the isolates while 18.1%, 12.6%, and 13.8% showed resistance to CZA, C/T, and CST, respectively. Conclusion CFDC demonstrated potent in vitro activity against the teat isolates collected from North America with greater than 99.6% of isolates having MIC values ≤4 mg/mL, including Carb-NS isolates of A. baumannii, P. aeruginosa, and Enterobacteriaceae. These findings indicate that this agent has high potential for treating infections caused by these problematic organisms. Disclosures M. Tsuji, Shionogi & Co., Ltd.: Employee, Salary. M. Hackel, IHMA, Inc.: Employee, Salary. Y. Yamano, Shionogi & Co., Ltd.: Employee, Salary. D. Sahm, IHMA, Inc.: Employee, Salary.

Comparative in vitro Activity of Cef epime and Four Extended-Spectrum Beta-Lactams on 1,251 Aminoglycoside-Resistant Gram-Negative Hospital Strains

Chemotherapy ◽  
1992 ◽  
Vol 38 (4) ◽  
pp. 225-231
Author(s):  
Raymond Vanhoof ◽  
Eric Nulens ◽  
Henry-Jean Nyssen ◽  
Eleonora Hannecart-Pokorni
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Beta Lactams ◽  
Gram Negative ◽  
Extended Spectrum

scholarly journals 1069. In Vitro Activity of Tebipenem Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S627-S627
Author(s):  
Bahgat Gerges ◽  
Joel Rosenblatt ◽  
Ray Y Hachem ◽  
Issam I Raad ◽  
Anne-Marie Chaftari
Keyword(s):  
Cancer Patients ◽  
Bacterial Infections ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Gram Negative Bacteria ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Patients With Cancer ◽  
Clinically Significant

Abstract Background Gram negative (GN) bacterial infections are on the rise in patients with cancer and frequently require extended hospital stays that may lead to a major increase in healthcare cost. This study aimed to evaluate the in vitro activity of a novel oral carbapenem, tebipenem against recent gram-negative clinical isolates from our cancer patients. Methods All 173 clinical isolates from our cancer patients including 36 Extended Spectrum Beta-Lactamase (ESBL) isolates from blood cultures were tested against tebipenem and other comparators. Clinical and Laboratory Standards Institute (CLSI) approved broth microdilution method was used. Appropriate ATCC controls were included. MIC50, MIC90, MIC ranges and percent of susceptibility calculations ware made using FDA breakpoints when available. The tebipenem provisional susceptibility breakpoint for most GN organism is ≤ 0.125 mg/L. Results Tebipenem and comparators antibiotics susceptibility percent (S: %), and MIC90 are shown in the table below. Tebipenem demonstrated highly potent activity against Escherichia coli, Klebsiella pneumoniae (including ESBL producing strains), Enterobacter cloacae and inhibited 90% of the Enterobacter aerogenes strains screened. MIC90s ranged from 0.06-0.25 mg/L for all tested Enterobacteriaceae. At a provisional breakpoints of 0.125 mg/L, the susceptibilities, MICs and ranges were comparable to meropenem, and ertapenem. Comparative study between Tebipenem and comparators for MIC90 (mg/L.) and Susceptibility (%) results against Gram-Negative Bacteria Isolated from Patients with Cancer Conclusion Our data demonstrate that oral tebipenem has promising activity against clinically significant bacterial pathogens isolated from cancer patients, and it has similar activity to that of other tested carbapenem. Further clinical evaluation for oral carbapenem treatment of bacterial infections is warranted. Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document